Dr Reddy’s wins exclusive private-market distribution rights for Takeda’s QDENGA in India
Dr Reddy’s will exclusively distribute and market Takeda’s dengue vaccine QDENGA in India’s private market. Takeda will retain public-market commercialisation, manufacturing and import responsibilities. Subject to local processes, availability is expected in the first half of 2027.
What happened
Dr. Reddy’s Laboratories · Dr Reddy's will exclusively distribute and market Takeda's QDENGA dengue vaccine in India’s private market, while Takeda retains
Key facts
- 2.09% share rise
- Rs 1,196.55 intraday high
- QDENGA approved for ages 4-60
- July 2026 CDSCO marketing authorisation
- First half of 2027 expected availability
What changed
Dr Reddy's will exclusively distribute and market Takeda's QDENGA dengue vaccine in India’s private market, while Takeda retains public-market commercialisation, manufacturing and importation responsibilities. The vaccine is expected to launch in the first half of 2027.
Why this matters
Dr Reddy’s gains exclusive private-market distribution rights for QDENGA, positioning its commercial network for a potential H1 2027 India launch while Takeda retains public-market responsibility.
What to watch
- Indian regulatory and local-process milestones confirming marketing, import and private-market availability.
- Takeda manufacturing output and India supply allocation for the initial launch period.
- Announced private-market price, reimbursement/insurance coverage and corporate-health adoption.
- Clinical and public-health guidance on dengue vaccination in India, including recommendations by age, prior exposure and geography.
- Dengue incidence trends, especially severe seasonal outbreaks that could accelerate demand.